The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The company is focussed on increasing the capacity utilizations while controlling costs
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Subscribe To Our Newsletter & Stay Updated
